Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Hyun Cheol Chung(Yonsei University), Patrick A. Ott(Dana-Farber Cancer Institute), Jean‐Pierre Delord, David Planchard(Université Paris-Saclay), Jaafar Bennouna(Hôpital Foch), Maya Gottfried(Meir Medical Center), Wilson H. Miller(Jewish General Hospital), Nicolas Penel(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Janice M. Mehnert(New York University), Kevin Norwood(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alona Zer(Rambam Health Care Campus), Shadia I. Jalal(Indiana University Health), Bo Gao(Sun Yat-sen University), Ignacio Matos(Vall d'Hebron Institute of Oncology), José A. López-Martín(Research Institute Hospital 12 de Octubre), Lei Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Suba Krishnan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dong‐Wan Kim(Seoul National University Hospital), Jan H.M. Schellens(Utrecht University), Steven Kao(Chris O’Brien Lifehouse), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center)
Cited by 437
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k